Evidence map›Paper›PMID 42313168›Full record

ArticleSurgery today2026

Cisplatin versus carboplatin as adjuvant chemotherapy for completely resected non-small cell lung cancer: a multicenter retrospective cohort study.

Masatsugu Hamaji, Ryo Miyata, Jiro Takeuchi, Naoki Ozu, Takuya Kohama, Ryota Sumitomo, Mamoru Takahashi, Takehisa Fukada, Megumi Kobayashi, Yosuke Kumaya and 1 more

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masatsugu HamajiDepartment of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8511, Nara, Japan. mhamaji@kuhp.kyoto-u.ac.jp.
Ryo MiyataDepartment of Thoracic and Cardiovascular Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8511, Nara, Japan.
Jiro TakeuchiInstitute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan.
Naoki OzuInstitute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan.
Takuya KohamaDivision of Thoracic surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Ryota SumitomoDepartment of Thoracic Surgery, Kyoto University, Kyoto, Japan.
Mamoru TakahashiDepartment of Thoracic Surgery, Otsu Red Cross Hospital, Shiga, Japan.
Takehisa FukadaDepartment of Thoracic Surgery, Amagasaki General Medical Center, Amagasaki, Japan.
Megumi KobayashiDepartment of Thoracic Surgery, Tenri Hospital, Tenri, Japan.
Yosuke KumayaDepartment of Thoracic Surgery, Kurashiki Central Hospital, Okayama, Japan.
Toyofumi Fengshi Chen-YoshikawaDepartment of Thoracic Surgery, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe current guidelines recommend cisplatin-based adjuvant chemotherapy for patients with completely resected stage II-III non-small cell lung cancer (NSCLC). Carboplatin-based chemotherapy is occasionally selected, although there is limited evidence of its long-term outcomes. We conducted this study to compare the long-term outcomes of cisplatin- based chemotherapy with those of carboplatin-based chemotherapy.

methodsA retrospective chart review was performed to identify patients aged ≥ 18 years with performance status 0-1, complete resection, and pathological stage II-IIIA NSCLC (7th edition) between 2014 and 2016 in our multi-institutional database. Patients were classified into two groups: the cisplatin-based adjuvant chemotherapy group and the carboplatin-based adjuvant chemotherapy group. To adjust for baseline differences, inverse probability of treatment weighting (IPTW) based on propensity scores was applied. The primary outcome was recurrence-free survival (RFS) and the secondary outcomes were cancer-specific survival (CSS) and overall survival (OS).

resultsA total 342 patients were included, of whom 195 received cisplatin-based adjuvant chemotherapy and 147 received carboplatin-based chemotherapy. After IPTW adjustment, the hazard ratios for RFS, CSS, and OS were 1.10 (95% confidence interval [CI]: 0.82-1.49, p = 0.526), 1.11 (95% CI: 0.68-1.82, p = 0.675), and 1.46 (95% CI: 0.96-2.22, p = 0.08), respectively.

conclusionsCarboplatin-based adjuvant chemotherapy may be considered for selected patients deemed unfit to receive cisplatin.

Indexed as

Antineoplastic AgentsCarboplatinCarcinoma, Non-Small-Cell LungCisplatinLung NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCohort StudiesFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTime FactorsAntineoplastic AgentsCarboplatinCisplatinChemotherapyLung cancerSurgerySurvival

Identifiers

PMID42313168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.